The results of this study appear in the November 2005 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/livertransplantation.
HIV-positive patients progress more rapidly to end-stage liver disease (ESLD), a condition requiring transplant, but post-transplant survival has improved in recent years, possibly because of advances in antiretroviral therapy. However, some patients do not survive long enough to undergo a transplant. Led by Margaret V. Ragni at the University of Pittsburgh School of Medicine, researchers studied whether poorer survival prior to transplant is related to the severity of either liver disease or HIV disease in these patients.
A total of 58 patients who were HIV-positive with ESLD were evaluated for transplant eligibility at the University of Pittsburgh Medical Center between 1997 and 2002. These patients were followed, along with 1,359 HIV-negative patients who were also evaluated for transplant. Of the 58 HIV-positive patients, 48 percent died before a transplant was performed, compared with 16 percent of the HIV-negative group. In addition, the survival period was much shorter in the HIV-positive group (880 versus 1,427 days), but the severity of their ESLD was no worse than the HIV-negative group. More than half of the deaths in
Contact: David Greenberg
John Wiley & Sons, Inc.